| Expression pattern: |
UP |
| Associated gene: |
ADAM10, Ago2 |
| Associated microRNA: |
miR-1270 |
| Biological function: |
CircCDYL promotes Ang II-induced VSMC injury, including reduced viability and proliferation and increased apoptosis, ferroptosis, and oxidative stress; circCDYL knockdown ameliorates these effects. |
| Molecular mechanism: |
CircCDYL functions as a miR-1270 sponge and positively regulates ADAM10 through the miR-1270/ADAM10 axis. |
| Biological pathway or process: |
proliferation (inhibits); apoptosis (promotes); ferroptosis (promotes); ceRNA regulation (other); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Annexin V/PI Flow Cytometry; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circCDYL may serve as a target for TAA treatment. |
| Description: |
circCDYL is up-regulated in TAA tissues and Ang II-treated human VSMCs. It promotes Ang II-induced VSMC injury by inhibiting viability/proliferation and enhancing apoptosis, ferroptosis, and oxidative stress. Mechanistically, circCDYL acts as a sponge for miR-1270 to positively regulate ADAM10, suggesting the circCDYL/miR-1270/ADAM10 axis as a potential therapeutic target in TAA. |
| Confidence score: |
0.8111 |